Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1442-2042.2011.02904.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypercontractile Esophagus Causing Midesophageal Diverticulum.
ACG Case Rep J
January 2025
Department of Gastroenterology and Hepatology, Dartmouth Health, Lebanon, NH.
Esophageal diverticulum (ED) is a rare condition with a clinical presentation that can be variable. Esophageal diverticulum has been associated with motility disorders; however, the association with mid-ED is less clear. Hypercontractile esophagus, also known as jackhammer esophagus, is a rare motility disorder of peristalsis diagnosed by esophageal high-resolution manometry after exclusion of mechanical obstruction.
View Article and Find Full Text PDFNavigating Language Barriers in Linguistically Complex Settings: A Qualitative Analysis of Paradoxes in Nurse Communication in Acute Care Units in Saudi Arabia.
ANS Adv Nurs Sci
January 2025
Author Affiliations: Faculty of Nursing, University of Tabuk, Tabuk, Saudi Arabia (Dr Alamrani); and Division of Nursing Science and Rutgers University Center for Health Equity and Systems Research, Newark, New Jersey (Dr Birnbaum).
This qualitative study explores how nurses managed communication challenges in linguistically complex Saudi Arabian acute care hospitals. A secondary analysis of transcripts from interviews with 21 nurses in Riyadh revealed the use of informal and creative strategies, including translation apps, non-verbal signaling, family interpreters, and an ad hoc system of sharing translation work among team members. In the absence of formal interpretation services, these strategies were essential but paradoxical, contributing to delays, errors, and team tension.
View Article and Find Full Text PDFPembrolizumab and axitinib induced pathological complete response in metastatic clear cell renal cell carcinoma with inferior vena cava thrombus: A case report.
SAGE Open Med Case Rep
January 2025
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Clear cell renal cell carcinoma is the predominant subtype of kidney cancer. With distant metastasis, the overall survival rate for patients with renal cell carcinoma decreases significantly compared to localized disease. However, pembrolizumab plus axitinib combination is safe and improves long-term survival.
View Article and Find Full Text PDFBackground: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.
View Article and Find Full Text PDFSpatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma.
J Immunother Cancer
January 2025
National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an, Shaanxi, China
Background: Clear cell renal cell carcinoma (ccRCC) is the most common histologic type of RCC. However, the spatial and functional heterogeneity of immunosuppressive cells and the mechanisms by which their interactions promote immunosuppression in the ccRCC have not been thoroughly investigated.
Methods: To further investigate the cellular and regional heterogeneity of ccRCC, we analyzed single-cell and spatial transcriptome RNA sequencing data from four patients, which were obtained from samples from multiple regions, including the tumor core, tumor-normal interface, and distal normal tissue.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!